Main Uses and Benefits of Halothane (Галотан)

Halothane is a medication generally used across conditions characterized by periods of heightened symptoms, specifically those that demand a profound, temporary lack of systemic response, such as major surgical interventions. Its primary benefit is to provide the state of General Anesthesia, managing symptom clusters that may become intense or disruptive during an operation.

Essential for General Anesthesia and Symptom Suppression

The medication plays a role in managing the symptoms of awareness, pain perception, and involuntary movement. It is commonly used for both the inhalation induction and maintenance of narcosis. It is particularly valued in clinical settings where a smooth start to anesthesia is desired, such as with pediatric patients, due to its supportive benefit for airway stability.

This agent plays a role in managing and easing symptoms related to acute pain and consciousness. Halothane supports the patient during difficult episodes by easing distress related to airway irritation, a symptom often seen in certain clinical settings. This agent also contributes to improved comfort during the start of the anesthetic state for patients of all ages, including children.

---

Quick Fact: Relief for Acute Systemic Symptoms Halothane helps address symptom clusters related to acute systemic responses (pain and awareness) and motor activity. It supports the patient during the temporary, high-stress conditions of surgery by providing controlled, reversible suppression of these symptoms.

Regulatory References

1. NIH StatPearls overview on General Anesthesia

Eligibility and Contraindications for Halothane

The eligibility for the use of Halothane is strictly defined by regulatory documents, focusing on patient populations and comorbidities where its use is restricted or prohibited.

Halothane is absolutely contraindicated in patients with a personal or family history of malignant hyperthermia susceptibility. Use is also prohibited in individuals with a history of unexplained jaundice or severe liver dysfunction following previous exposure to Halothane.

Specific restrictions apply to conditional use. In patients with markedly raised intracranial pressure, administration is permitted only if preceded by specific measures to reduce the pressure. Furthermore, the simultaneous use of catecholamines, such as epinephrine or norepinephrine, is restricted due to the risk of inducing ventricular arrhythmias.

Regarding special populations, Halothane is classified as Pregnancy Category C; routine use is not recommended during early pregnancy unless the benefit clearly outweighs potential risk. It is also contraindicated for routine obstetrical delivery. While established for general anesthesia in adults and children, its use in neonates and infants requires particular caution due to a heightened cardiac depressant effect.

The official regulatory documents define the interaction profile of Halothane primarily based on pharmacodynamic potentiation, metabolic risk, and mandatory restrictions.

A significant interaction restriction involves sympathomimetics (such as adrenaline or norepinephrine), which are severely restricted or contraindicated due to the documented risk of inducing serious ventricular arrhythmias.

Interaction Category	Regulatory Outcome / Restriction
Pharmacodynamic Potentiation	Halothane augments the effect of non-depolarizing muscle relaxants (e.g., Tubocurarine), necessitating official recognition of the enhanced blockade. Co-administration with Beta-blockers or Calcium Channel Blockers may enhance the hypotensive effect.
Metabolic Risk	The official label links chronic exposure to alcohol and enzyme inducers like Phenobarbitone to an increased potential for hepatotoxicity via enhanced metabolic activation.
Timing Rules	Monoamine Oxidase Inhibitors (MAOIs) should be discontinued for 14 days prior to administration to avoid documented hazardous interactions.
Population-Specific Constraint	In obstetrics, Halothane causes marked uterine relaxation, which is documented to inhibit the action of oxytocic agents (e.g., Ergometrine) used to control bleeding.

Furthermore, subsequent Halothane use is strictly prohibited in any patient who has developed unexplained jaundice or pyrexia following a previous exposure. The interaction structure is governed by formal statements detailing which substances are contraindicated, how the interaction is officially described (e.g., enhanced cardiosensitization or potentiation), and under what labeled conditions the combination applies.

Галотан is a volatile halogenated hydrocarbon that distributes rapidly through the systemic circulation to tissues, including the central nervous system. Its primary molecular mechanism involves modulation of multiple ligand-gated and voltage-gated ion channels.

At the GABAA receptor, галотан acts as a positive allosteric modulator, increasing the chloride ion flux through the channel pore following the binding of the gamma-aminobutyric acid neurotransmitter. This enhanced inhibitory signal leads to neuronal hyperpolarization and decreased excitability in the central nervous system.

Simultaneously, галотан functions as an antagonist at the N-methyl-D-aspartate (NMDA) receptor, blocking the excitatory effects of glutamate. It also inhibits nicotinic acetylcholine (nACh) receptors and voltage-gated sodium channels, thereby depressing nerve conduction and transmission of action potentials. Furthermore, it activates certain twin-pore potassium channels (e.g., K2P channels), which contributes to cellular hyperpolarization.

The resulting cumulative effects include depression of synaptic transmission in key neuronal circuits, which leads to a generalized decrease in whole-brain electrical activity, resulting in a system-level state of central nervous system depression, decreased cardioregulatory function, and reduced skeletal muscle tone.

Instruction Map: How to use Галотан — Official Administration Guidelines

Feature	Description
Route of administration	Inhalation of the vaporized liquid.
Dosing schedule (Adults)	Induction ranges from 2% to 4% (v/v) concentration in the inspired gas mixture. Maintenance is sustained between 0.5% and 2% (v/v).
Timing in relation to meals	Not applicable; administration is strictly restricted to a hospital-controlled setting.
Preparation requirements	The liquid is administered using a calibrated vaporizer designed for volatile agents. The formulation includes 0.01% thymol to stabilize the product.
Age-group administration rules	Pediatric Induction utilizes 1.5%-2% (v/v) concentration. For Older Adults, the lowest maintenance concentrations, such as 0.5% v/v, are generally suitable for sustaining the anesthetic state.
Missed-dose rules	Not applicable, as administration is a single, continuous event for the duration of the surgical procedure.
Special procedural conditions	Use is strictly restricted to specialist hospital environments. Vaporizers should be positioned out of the breathing circuit in closed rebreathing systems to ensure accurate dosage control.

---

Instruction Classifications (High-Level)

Classification	Value
Administration method type	Inhaled Volatile Agent
Frequency pattern	Single-event, Continuous Administration (Short-term)
Regulatory basis	Based on established pharmaceutical standards.
Use-context constraints	Restricted to hospital or specialist settings.

---

Resulting Procedural Structure

Official step sequence:

• The Halothane liquid is vaporized using specialized equipment.
• The concentration is set higher for the Induction Phase to rapidly achieve the anesthetic state.
• The concentration is reduced and maintained during the Maintenance Phase for the duration of the procedure.

Connection to the Overall Use Protocol

The official use protocol for Halothane establishes a controlled, sequential two-phase process that is critically dependent on specialized delivery equipment and continuous professional monitoring. This protocol mandates precise concentration ranges for both the Induction and Maintenance phases and outlines specific adjustments for pediatric and elderly patients, defining a standardized approach to administration.

Research evidence / Overview of studies for Галотан

Evidence for the Induction and Maintenance of General Anesthesia

Clinical study has explored the use of Halothane (Галотан) in surgery, encompassing early clinical trials, large-scale observational studies, and later Randomized Controlled Trials (RCTs) that compare it to newer anesthetic agents. Research examined how Halothane was studied for achieving the necessary state of unconsciousness (narcosis) and maintaining the state of narcosis required for a procedure. Studies monitored physiological outcomes such as heart rate and blood pressure, as well as the need for additional pain-blocking medications. Findings describe patterns observed in the studies related to the time it takes for anesthesia to begin and the required concentration. Historically, the evidence base includes large studies designed to observe trends and associations among different anesthetic agents, adding to the historical evidence base. These findings help contextualize how the drug was studied and how patients reported their experience immediately after surgery.

---

Studies in Special Populations, Including Pediatric Patients

Halothane was evaluated in various patient populations, including adults undergoing major surgery. Research has also specifically explored its use in children (pediatric patients). These studies monitored outcomes related to the ease of induction—the process of falling asleep—due to its characteristics observed during the induction of narcosis. Studies focused on episodes where symptoms become more noticeable, such as during the start of anesthesia in children, where studies observed patterns related to physiological responses. While the research describes the drug's short-term characteristics across different age groups, data for certain other groups remain insufficient. Results primarily apply only to the populations studied and provide limited insight into a full range of specific clinical scenarios.

---

Long-Term Follow-up and Extended Data

The primary research focus for Halothane was on outcomes that occur during the procedure and in the immediate postoperative period (the first hours to a day). The largest historical observational studies did monitor patients for longer periods (days or weeks) to observe broad patterns in systemic or functional imbalance following surgery. However, long-term effects are not fully established by controlled research. Follow-up durations were limited in most of the comparative trials. Research has explored short-term symptom changes but provides limited information for long-term outcomes, such as neurocognitive function or the durability of the initial therapeutic effect years later. Therefore, outcomes reflecting daily functioning or activity level months after exposure are not well characterized in the existing clinical evidence.

---

Evidence Quality, Limitations, and Research Gaps

The available evidence quality varies across studies. A significant portion of the primary data is older, meaning that the methodology and comprehensive outcome reporting may not meet the standards of modern RCTs. Furthermore, much of the more recent, high-quality research on Halothane is focused on comparing it to newer agents rather than re-establishing its own primary characteristics. Historical observational studies describe associations but are not based on randomized control. Consequently, data for certain groups remain insufficient, and research is still ongoing, particularly regarding longer-term outcomes. The findings describe group patterns, and research provides context, but it does not determine whether an individual will respond similarly.

Key Studies & References

1. A comparison between the effect of halothane and propofol on liver enzymes after general anesthesia
2. Halothane - eEML - Electronic Essential Medicines List (WHO)

Common questions about Галотан (FAQ)

Q: What is Галотан (Halothane) used for?

Halothane is a general anesthetic used to prevent pain and cause temporary loss of consciousness for surgical procedures. It is inhaled through a mask or breathing tube, and its purpose is to keep the patient asleep during an operation.

---

Q: How does Halothane work?

Halothane is a volatile liquid that is administered as a vapor. It works by depressing the central nervous system, which results in general anesthesia. The exact mechanism is complex, but it affects the way nerve cells communicate, leading to a temporary state of unconsciousness and muscle relaxation.

---

Q: What are the risks of using Halothane?

While Halothane is effective, its use has been associated with a few significant risks. The main concerns include:

• Hepatotoxicity: In rare cases, Halothane can cause severe liver damage (halothane hepatitis), particularly after repeated exposure.
• Cardiac Effects: It can depress the heart's function and lead to abnormal heart rhythms (arrhythmias).
• Malignant Hyperthermia: Although rare, Halothane can trigger a life-threatening, rapid rise in body temperature in susceptible individuals.

Due to these risks, newer general anesthetics are often preferred, and Halothane is no longer widely used in many developed countries.

---

Q: Who should not receive Halothane?

Halothane may not be suitable for people with certain health conditions. Patients who have a history of halothane-associated hepatitis or unexplained fever after previous exposure should generally not receive it. It is also typically avoided in individuals with a known or suspected predisposition to malignant hyperthermia.

Storage and Disposal of Halothane (Fluothane)

Halothane must be stored at controlled room temperature in a tightly closed container and requires protection from light to prevent degradation, according to regulatory labeling. The volatile liquid is stabilized with 0.01% thymol. A key in-use storage rule is that anesthetic vaporizers must be emptied at the end of each operating day to prevent the accumulation of non-volatile thymol.

Yellow discoloration of the liquid indicates product degradation, and the discolored Halothane must be discarded. Unused medication must be kept out of the sight and reach of children. For disposal, preferred methods include drug take-back programs. In the clinical setting, waste anesthetic gas must be managed using specialized scavenging systems.